Acute Pancreatitis Market Size Report | Share Analysis 2030

The acute pancreatitis market size is expected to grow from US$ 5,649.77 million in 2022 and is expected to reach a value of US$ 8,827.37 million by 2030; it is anticipated to record a CAGR of 5.7% from 2022 to 2030.

Market Insights and Analyst View:

The acute pancreatitis market size is growing rapidly due to an upsurge in the number of acute pancreatitis cases due to an increase in cases of gallstones. Also, a rise in the incidence of diabetes fuels the growth of the market.

 In September 2022, GE Healthcare received a US FDA 510(k) clearance for its breakthrough AIR Recon DL for the 3D and PROPELLER imaging sequences. These new features extend the benefits of AIR Recon DL to nearly all magnetic resonance imaging (MRI) clinical procedures, encompassing all anatomies and enabling shorter scan times, better image quality, and enhanced patient experience. Thus, a significant rise in revolutionary technologies to address customer needs is likely to bring new trends in the acute pancreatitis market during the forecast period.

Future Trends and Challenges:

Acute pancreatitis is an inflammatory disorder of the pancreas. The condition is associated with increased morbidity and mortality because there is no specific treatment approved to treat it, leaving supportive care as the main course of treatment. A targeted novel treatment strategy that halts disease progression and improves patient outcomes is needed to address the current disease burden of acute and severe pancreatitis. An article published in the National Library of Medicine in February 2023 focuses on 3 major approaches to advance acute pancreatitis treatments—the clinical identification and application of new genetic information; newly identified serum biomarkers, i.e., fatty acid ethyl esters (FAEEs); and acceleration in timing of early nutrition feedings in acute pancreatitis.

Clinical Identification and Application of New Genetic Information:

When acute pancreatitis occurs at the age of 35 years or when it is relapsing or idiopathic, testing for the 6 commercially evaluable genetic causes of acute pancreatitis is recommended. This test provides valuable information regarding the diagnosis probability of genetic predisposition, cofactors that are likely to play a role in disease identification and a suitable approach to initiate treatment early in the process, without requiring repeated testing.

Newly Identified Serum Biomarkers—FAEEs:

During a prospective, blinded trial, researchers compared the levels of FAEE, nonesterified fatty acids, and ethanol in the blood of 175 patients hospitalized for alcoholic pancreatitis, alcohol intoxication, nonalcoholic pancreatitis, and normal controls. This test has the unique capability of demonstrating diagnostic elevations of FAEEs associated with alcohol consumption. Therefore, it can be evaluated that alcohol is the cause of alcohol-associated pancreatitis.

Important Acceleration in Timing of Early Feedings in Acute Pancreatitis:

The practice of beginning early feeding through the nasogastric/nasojejunal routes after the onset of acute pancreatitis has been supported by multiple randomized controlled trials and has replaced the practice of resting the gastrointestinal tract until pain subsides prior to feeding. This approach results in increased bowel motility and reduced organ failure, infection, length of stay, and mortality rates, confirming that an idle intestine leads to bacterial overgrowth, increased permeability, and bacterial translocation.

Such developments in specific treatment approaches would lead to new treatment options to enhance outcomes and improve the acute pancreatitis market in the near future.  

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Acute Pancreatitis Market: Strategic Insights

Market Size Value in	US$ 5,649.77 million in 2022
Market Size Value by	US$ 8,827.37 million by 2030
Growth rate	CAGR of 5.7% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The acute pancreatitis market share is segmented on the basis of offerings, application, and end user. Based on offerings, the market is classified into medication, diagnosis, and others. Based on causes, the acute pancreatitismarket is segmented into gallstones, alcoholism, genetic disorders, infection, and others. Based on end user, the market is classified into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. Based on geography, the acute pancreatitis market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

Based on offerings, the acute pancreatitis market is segmented into medication, diagnosis, and others. In 2022, the diagnosis segment held the largest share of the market. However, the others segment is expected to record the fastest CAGR during the forecast period (2022-2030). The acute pancreatitis market for the diagnosis segment is further segmented into blood tests, CT scans, stool tests, ultrasound, MRI, and urine tests. Blood tests are primarily used to diagnose acute pancreatitis. An elevated level of pancreatic enzymes such as amylase and lipase in a blood sample indicates the presence of the disease. Similarly, urine tests are used to detect trypsinogen-2 or amylase levels to diagnose pancreatic problems, including pancreatitis.

Further, a stool elastase test measures the amount of elastase in the stools. Limited or no elastase found in the stool indicates that the pancreas can't make/release enough elastase and other digestive juices. This condition is called exocrine pancreatic insufficiency (EPI). According to MedlinePlus (United States National Library of Medicine), acute (short-term) pancreatitis is one of the causes of EPI. Thus, stool tests can also be used to diagnose acute pancreatitis. Imaging tests such as ultrasound, CT scan, and MRI are widely used to visualize the pancreas and nearby tissues to identify abnormalities or inflammation. These tests help determine the severity of the disease. It helps clinicians to provide proper treatment guidance, as an accurate diagnosis is crucial for the effective management of acute pancreatitis.

Acute Pancreatitis Market, by Offerings – 2022 and 2030

Access Data

Based on causes, theacute pancreatitis market is classified into gallstones, alcoholism, genetic disorders, infection, and others. In 2022, the gallstones segment held the largest share of the market. The same segment is expected to record the highest CAGR rate during the forecast period (2022-2030). Cholelithiasis, commonly known as gallstones, are hardened deposits of digestive fluid, such as cholesterol or bilirubin, that can form in the gallbladder. According to Johns Hopkins Medicine, when a gallstone blocks a patient’s pancreatic duct, it causes pancreatitis. The main symptoms of gallstone pancreatitis are severe pain, fever, jaundice, nausea, etc. Acute pancreatitis can be diagnosed using blood tests and different imaging devices. Blood tests can identify inflammation in the pancreas. A CT scan, MRI, or ultrasound can help diagnose the severity of the condition. According to the National Institute for Health and Care Excellence (NICE), the prevalence of gallstones is ~10–15% of adults in Europe and the US. As per a study published in April 2023 in PubMed Central, the global incidence of gallstones varies between 3% and 21.9%. Thus, the high prevalence of gallstones propels the acute pancreatitis market growth for the gallstones segment.

Based on end user, the acutepancreatitismarket is classified into hospitals, diagnostic laboratories, ambulatory surgical centers, and others. In 2022, the hospitals segment held the largest share of the market. The acute pancreatitismarket for the diagnostic laboratories segment is estimated to grow at a CAGR of 6.4% during the forecast period (2022-2030). Acute pancreatitis is treated mainly in hospitals through surgery, tissue removal procedures, and ERCP. Most surgeries are performed in hospitals as they provide continuous patient care and monitoring. The growing geriatric population and the increasing number of hospitals across the world are contributing to the acute pancreatitis market progress. The geriatric population is more than twice as likely to need hospitalization as adults in the middle age. According to a study published in November 2021 in Wolters Kluwer, ~17% of Americans aged 65 years and above get hospitalized at least once during the year, whereas only 8% of adults aged 45–64 years required hospitalization. Older adults have a similar average length of stay (5 days) compared to adults aged 45–64.

Regional Analysis:

Based on geography, the acute pancreatitis market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the global market growth, and Asia Pacific is expected to register the fastest CAGR during 2022–2030. The acute pancreatitis market in North America is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share in this region and is expected to continue its dominance during the forecast period (2022-2030). The acute pancreatitis market in North America is expected to grow due to the increasing burden of the disease with an increase in the number of gallstone cases and excessive consumption of alcohol. Also, technological advancements in healthcare facilities are benefitting the acute pancreatitis market in North America. The US reports an increasingly large number of acute pancreatitis cases due to a wide-scale practice of alcohol consumption and an upsurge in the cases of gallstones. According to the 2021 National Survey on Drug Use and Health (NSDUH), ~174.3 million people in the US aged 12 and above consumed alcohol in 2020. Data released by the Substance Abuse and Mental Health Services Administration (SAMHSA) in 2021 stated that ~29.5 million population aged more than 12 years and ~27.4 million population aged more than 21 years in the US suffer from alcohol use disorder. Excessive alcohol consumption is an important cause of acute pancreatitis. According to a recent report by the Centers for Disease Control and Prevention (CDC), deaths from alcohol-induced acute pancreatitis increased by 50% during 2019–2020. According to Medscape data, ~40–50 acute pancreatitis cases per 100,000 adults are registered in the US every year, and nearly 275,000 hospital admissions in the country are due to acute pancreatitis. A rise in hospital admissions due to acute pancreatitis fuels the growth of the market in the US.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the acute pancreatitis market are listed below:

1. In May 2023, Royal Philips announced the launch of the Philips CT 3500, a new high-throughput CT system targeting the needs of routine radiology and high-volume screening programs. Powered by AI, the Philips CT 3500 includes a range of image-reconstruction and workflow-enhancing features that help deliver consistency, speed, and first-time-right image quality, which aids in reliable diagnoses by clinicians and improves return on investment, even in the most demanding, high-volume care settings.
2. In March 2022, Fresenius Kabi closed the acquisition of Ivenix, Inc. (“Ivenix”), a specialized infusion therapy company. Ivenix adds a next-generation infusion therapy platform to Fresenius Kabi’s portfolio for the significant US market, which provides the company with key capabilities in hospital connectivity and interoperability. The combination of Ivenix’ leading hardware and software products with Fresenius Kabi’s intravenous fluids and infusion devices would allow them to create a comprehensive and leading setup of premium products. With such developments, both these companies have taken steps toward achieving sustainable growth in the high-value MedTech space.
3. In October 2021, Samsung Medison, an affiliate of Samsung Electronics (global medical equipment company), introduced the new V8 high-end ultrasound system that provides enhanced image quality, usability, and convenience for all medical professionals.

Competitive Landscape and Key Companies:

A few of the prominent players operating in the acute pancreatitis market are Abbott Laboratories, GE HealthCare Technologies Inc, Samsung Healthcare, Koninklijke Philips NV, Baxter International Inc, Dynavax Technologies Corp, Actim Oy, Medtronic Plc, Boston Scientific Corp, and Fresenius Kabi AG. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. Their global presence allows them to serve a large set of customers, subsequently allowing them to expand their market share.